Market atlas / Incretins / Tirzepatide

Tirzepatide (GIP / GLP-1 dual agonist)

repurposedpeptidegip-receptor-agonismglp1-receptor-agonismweight-loss● body-weight● hba1c

Stage by geography

Same development stage across markets, but Japan reached it about 4 years before China.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKRIN+1 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	class Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]; GLP-1 Receptor Agonist [EPC]
UK	approved	2024-01-25	indication Mounjaro is indicated: 1. For the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus…
CN	approved	2026-06-30	form Injection, chemical drug
IN	RCT	2025-10-15	not published
JP	approved	2022-09-26	indication Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus.
CH	approved	2022-11-02	indication Type 2 diabetes mellitus; weight management
SG	approved	2023-03-01	form Injection, solution, subcutaneous, prescription only
IL	approved	2023-03-14	indication T2DMMounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as…
KR	approved	2023-06-28	class Diabetes agents [MFDS 03960]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA H20265062. Domestic generics vs imported originator.

4domestic approvals

Forms listed: 1
Product: Tirzepatide Injection
Form: injection
Strength: calc. as C₂₂₅H₃₄₈N₄₈O₆₈, 2.4ml:20mg (per unit: 4dose0.6ml : 5mg)
Holder: Eli Lilly Suzhou Pharmaceutical
Origin: China
Approved: 2026-06-30
Approval no: NMPA H20265062

8imported approvals

approval count only; per-product detail not captured

Biomarker trends

no biomarker readings yet

Studies

The studies on Tirzepatide, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse…	IL, IN, JP, KR
Percent Change From Baseline in Body Weight	IN, JP
Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline	IN, JP
Relative change in body weight	IN, JP
Change from Baseline in Hemoglobin A1c (HbA1c)	IL, JP
Change in glycated haemoglobin (HbA1c)	IN
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug…	IN
Change TIR	CH
Percent Change from Baseline in Body Mass Index (BMI)	IL
A Composite Endpoint of Normalization or Clinically Significant Improvement in At Least 2 Predefined Weight-Related Comorbidities…	IL

Connections

Trajectory

2022

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:tirzepatide (2022-09-26) · machine-extracted

2022

MarketCH: approved-other (Swissmedic-authorised (Switzerland))

Swissmedic:tirzepatid (2022-11-02) · machine-extracted

2023

MarketSG: approved-other (HSA-registered (Singapore))

HSA:tirzepatide (2023-03-01) · machine-extracted

2023

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:tirzepatide (2023-03-14) · machine-extracted

2023

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:tirzepatide (2023-06-28) · machine-extracted

2024

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:tirzepatide (product 15484) · machine-extracted

2025

Relatedshares a mechanism with Semaglutide

NCT06737042 · machine-extracted

2025

ProfileTirzepatide (GIP / GLP-1 dual agonist)

NCT06737042 · machine-extracted

2025

MarketIN: rct (clinical trials (highest phase 3))

NCT07165028 · machine-extracted

2026

MarketCN: approved-other (NMPA-approved (domestic + imported))

NMPA:NMPA H20265062 · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 3))

NCT07165028 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 3))

NCT07165028 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 3))

NCT05412004 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 3))

NCT07165028 · machine-extracted

2026

MarketSG: first-in-human (clinical trials (highest phase 1))

NCT02759107 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

NDA215866 · machine-extracted

Get into the weeds: raw observations + provenance

pmda__dev_tirzepatide__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Tirzepatide (Mounjaro Subcutaneous Injection 2.5 mg Ateos Mounjaro Subcutaneous Injection 5 mg Ateos Mounjaro Subcutaneous Injection 7.5 mg Ateos Mounjaro Subcutaneous Injection 10 mg Ateos Mounjaro Subcutaneous Injection 12.5 mg Ateos Mounjaro Subcutaneous Injection 15 mg Ateos (Eli Lilly Japan K.K.)), first approval 2022-09-26. [PMDA List of Approved Drugs]
   source PMDA:tirzepatide (2022-09-26)  https://www.pmda.go.jp/files/000281190.pdf

swissmedic__dev_tirzepatide__CH  2026-07-13  kind=geography_stage  verify=M
   Swissmedic-authorised in Switzerland: tirzepatidum (Mounjaro 2.5 mg, solution for injection, prefilled pen), first authorisation 2022-11-02. [Swissmedic list of authorised medicinal products]
   source Swissmedic:tirzepatid (2022-11-02)  https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx

hsa__dev_tirzepatide__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: Tirzepatide (MOUNJARO INJECTION 7.5MG/0.5ML), first registration 2023-03-01. [HSA Listing of Registered Therapeutic Products]
   source HSA:tirzepatide (2023-03-01)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

israelmoh__dev_tirzepatide__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): TIRZEPATIDE 20 MG/ML (MOUNJARO 10 MG/0.5 ML), current registration 2023-03-14. [Israel MoH Drug Registry]
   source IsraelMoH:tirzepatide (2023-03-14)  https://israeldrugs.health.gov.il/

mfds__dev_tirzepatide__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Tirzepatide (Mounjaro Prefilled Pen Inj. 10mg/0.5mL(Tirzepatide)), first approval 2023-06-28. [MFDS drug product-approval list]
   source MFDS:tirzepatide (2023-06-28)  https://nedrug.mfds.go.kr/pbp/CCBGA01

tirz_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: Mounjaro KwikPen 10mg solution for injection in pre-filled pen [active substance: tirzepatide], first authorised 2024-01-25. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:tirzepatide (product 15484)  https://www.medicines.org.uk/emc/product/15484/smpc

tirz_edge_sema  2026-06-29  kind=edge  verify=M
   both incretin agonists (tirzepatide adds GIP to GLP-1)
   source NCT06737042  https://clinicaltrials.gov/study/NCT06737042

tirz_facets  2026-06-29  kind=facets  verify=M
   Tirzepatide facets
   source NCT06737042  https://clinicaltrials.gov/study/NCT06737042

tirz_in  2026-06-29  kind=geography_stage  verify=M
   Tirzepatide: registered phase 3 trial in India [NCT07165028]
   source NCT07165028  https://clinicaltrials.gov/study/NCT07165028

tirz_cn  2026-06-29  kind=geography_stage  verify=M
   NMPA-approved in China (tirzepatide): 4 domestic approval(s) (e.g. Tirzepatide Injection, calc. as C₂₂₅H₃₄₈N₄₈O₆₈, 2.4ml:20mg (per unit: 4dose0.6ml : 5mg) , Eli Lilly Suzhou Pharmaceutical, China); 8 imported approval(s). Reference NMPA H20265062.
   source NMPA:NMPA H20265062  https://www.nmpa.gov.cn/datasearch/home-index.html

ctsearch__CH__dev_tirzepatide  2026-07-10  kind=geography_stage  verify=M
   tirzepatide: 3 registered trial(s) in CH, highest phase 3 [NCT07165028]
   source NCT07165028  https://clinicaltrials.gov/study/NCT07165028

ctsearch__IL__dev_tirzepatide  2026-07-10  kind=geography_stage  verify=M
   tirzepatide: 15 registered trial(s) in IL, highest phase 3 [NCT07165028]
   source NCT07165028  https://clinicaltrials.gov/study/NCT07165028

ctsearch__JP__dev_tirzepatide  2026-07-10  kind=geography_stage  verify=M
   tirzepatide: 17 registered trial(s) in JP, highest phase 3 [NCT05412004]
   source NCT05412004  https://clinicaltrials.gov/study/NCT05412004

ctsearch__KR__dev_tirzepatide  2026-07-10  kind=geography_stage  verify=M
   tirzepatide: 5 registered trial(s) in KR, highest phase 3 [NCT07165028]
   source NCT07165028  https://clinicaltrials.gov/study/NCT07165028

ctsearch__SG__dev_tirzepatide  2026-07-10  kind=geography_stage  verify=M
   tirzepatide: 3 registered trial(s) in SG, highest phase 1 [NCT02759107]
   source NCT02759107  https://clinicaltrials.gov/study/NCT02759107

openfda__NDA215866__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (TIRZEPATIDE); approved, marketed [NDA215866]
   source NDA215866  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA215866